Briumvi

Active Ingredient(s): Ublituximab-xiiy
FDA Approved: * December 28, 2022
Pharm Company: * TG THERAPEUTICS, INC
Category: Multiple Sclerosis
* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Briumvi 25 mg/ml Intravenous Injection, Solution, Concentrate
NDC: 73150-150
Labeler:
Tg Therapeutics, Inc.